IFP Advisors’s AIM ImmunoTech AIM Stock Holding History

IFP Advisors’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1	Closed	-$226	–	3385
2020 Q4	$0	Buy	+1	New	+$200	﹤0.01%	3256

Other funds holding AIM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

IFP Advisors's AIM Position: Q1 2021 in Review

IFP Advisors sold out of AIM ImmunoTech (AIM) in Q1 2021, closing a stake of 1 share — an estimated $226 sold.

IFP Advisors first reported a position in AIM in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 35 funds tracked by Wall St. Rank hold AIM as of Q1 2021.

IFP Advisors reported no remaining AIM ImmunoTech position as of Q1 2021 after selling out during the quarter.
IFP Advisors sold 1 AIM ImmunoTech share in Q1 2021, an estimated $226.
IFP Advisors first reported a position in AIM ImmunoTech in Q4 2020 and held it in 1 quarter.
IFP Advisors's AIM ImmunoTech position peaked at $0 in Q4 2020.
35 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q1 2021.

Based on IFP Advisors's 13F filing for Q1 2021, filed 30 Apr 2021.